Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Persistent Corneal Epithelial Defect Clear all
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
KB801, Placebo
Biological · Drug
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Irvine, California • Pasadena, California • Carmel, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 8:07 PM EDT
Not yet recruiting Phase 3 Interventional
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Chesterfield, Missouri • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 8:07 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect
Interventions
ST266, 0.67% Sodium Chloride Ophthalmic Solution, Open-label ST266
Biological · Other
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
31
States / cities
Dothan, Alabama • Little Rock, Arkansas • Huntington Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders
Interventions
Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced May 21, 2026, 8:07 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect
Interventions
KPI-012, KPI-012 Vehicle
Drug
Lead sponsor
Combangio, Inc
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
43
States / cities
Dothan, Alabama • Irvine, California • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced May 21, 2026, 8:07 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Cornea
Interventions
carboxymethylcellulose sodium, Acuvue Oasys Bandage Contact Lens, Ambiodisk, Prokera
Drug · Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced May 21, 2026, 8:07 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect
Interventions
ST266
Biological
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Indianapolis, Indiana • Edgewood, Kentucky • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced May 21, 2026, 8:07 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Corneal Persistent Epithelial Defect
Interventions
Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle, Open-label Nexagon® (lufepirsen)
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect
Interventions
lufepirsen high dose, Vehicle, lufepirsen low dose
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
2 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Dothan, Alabama • Petaluma, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced May 21, 2026, 8:07 PM EDT